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FIRST CLINICAL CASE REPORTOchromobactrum intermedium: an emerging opportunistic pathogen—case
of recurrent bacteraemia associated with infective endocarditis in a
haemodialysis patientT. Bharucha1,2, D. Sharma1, H. Sharma1, H. Kandil3 and S. Collier1
1) Royal Free Hospital NHS Foundation Trust, 2) University College London, London and 3) West Hertfordshire NHS Foundation Trust, Stevenage, UKAbstractWe describe the ﬁrst clinical case report of infective endocarditis related to Ochrobactrum intermedium infection. The case involved a 23-year-
old man receiving dialysis via an internal jugular long-term haemodialysis catheter. He improved with a prolonged course of meropenem and
minocycline. Ochrobactrum spp. are recognized as rare emerging opportunistic pathogens.
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E-mail: t.bharucha@doctors.org.ukA 23-year-old male haemodialysis patient attended the emer-
gency department with fever and rigors 10 days after a 2-week
visit to Pakistan. He had bilateral renal dysplasia, with a failed
renal transplant while receiving immunosuppression, and was
undergoing dialysis via a right internal jugular long-term hae-
modialysis catheter. He had received maintenance haemodial-
ysis at a medical centre in Pakistan.
On examination, his blood pressure was 99/37 mm Hg, pulse
140 beats per minute and temperature 37.7°C. General ex-
amination was unremarkable, with no features of infective
endocarditis noted. Investigations revealed a white blood cell
count of 7 × 109/L, C-reactive protein of 146 mg/L and normal
chest X-ray. In the absence of an obvious septic focus, he
received intravenous (iv) ﬂucloxacillin and gentamicin for
catheter-related septicaemia as per hospital guidelines.
Admission blood culture (BC) of samples taken from the
long-term haemodialysis catheter were positive at 24 hours
with Gram-negative rods identiﬁed as Ochrobactrum spp. by
matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS; Bruker Microﬂex, Biotyperw Microbe and New Infect 2017; 15: 14–15
2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2016.09.0163.1; Bruker Daltonics, Bremen, Germany) and O. intermedium
by the reference laboratory by partial sequencing of the 16S
ribosomal RNA gene. Repeat long-term haemodialysis catheter
BC of samples taken 24 and 48 hours after admission and pe-
ripheral BC of samples taken 96 hours after admission
remained positive for Ochrobactrum spp. The catheter was
removed, and antibiotic therapy was switched to meropenem
1 g iv twice daily, to continue 48 hours after line removal. He
improved and was discharged.
Two months later he again sought care for fever and
shortness of breath. At examination he had pulmonary oedema
with a raised C-reactive protein of 79 mg/L. BC of samples
taken at admission grew Ochrobactrum spp. after 31 hours. On
the basis of reference laboratory susceptibilities he was treated
with meropenem 1 g iv twice daily and tigecycline 50 mg iv
twice daily. Transthoracic echocardiography demonstrated a
1.32 cm2 right atrial vegetation. He developed sudden hypoxia,
and computed tomographic pulmonary angiography revealed a
right lung pulmonary embolus; he commenced anticoagulation
therapy. Five days later he developed abdominal pain with
amylase 267 U/L. Computed tomography conﬁrmed pancrea-
titis. Because of this recognized tigecycline complication, tige-
cycline was switched to minocycline 100 mg iv twice daily. He
was discharged 2 weeks later to complete 6 weeks of treatment
with meropenem and minocycline. Repeated BC analyses have
since been negative.iology and Infectious Diseases
nses/by-nc-nd/4.0/)
TABLE 1. Ochrobactrum intermedium isolates with antibiotic susceptibility in chronological order
Date Source Conditions Identiﬁcation Susceptibility (in house)
Antibiotic MIC Interpretation
25/9/15 iv line Aerobic BACTEC bottle after 25 hours Ochrobactrum intermedium
(laboratory reference)
Ciproﬂoxacin
Amikacin
Colistin
Meropenem
2
>256
>256
>32
Intermediate
Resistant
Resistant
Resistant
26/9/15 iv line Aerobic BACTEC bottle after 24 hours Ochrobactrum spp. Not performed — —
27/9/15 iv line Aerobic BACTEC bottle after 15 hours Ochrobactrum spp. Not performed — —
29/9/15 Peripheral Aerobic BACTEC bottle after 21 hours Ochrobactrum spp. Not performed — —
21/11/15 iv line Aerobic BACTEC bottle after 33 hours Ochrobactrum intermedium Ertapenem
Meropenem
Tigecycline
Ciproﬂoxacin
Colistin
Fosfomycin
0.5
1.5
1.5
4
>256
>1024
Susceptible
Susceptible
Susceptible
Resistant
Resistant
Resistant
24/11/15 iv line Aerobic BACTEC bottle after 31 hours Ochrobactrum spp. Tigecycline
Ertapenem
Meropenem
Colistin
Imipenem
Cotrimoxazole
Ciproﬂoxacin
1.5
1.5
3
>256
12
6
6
Susceptible
Intermediate
Intermediate
Resistant
Resistant
Resistant
Resistant
iv, intravenous; MIC, minimum inhibitory concentration.
NMNI Bharucha et al. Ochrobactrum intermedium 15Ochrobactrum spp. are non-lactose-fermenting, Gram-nega-
tive rods that belong to the genus Brucella. The most common
species identiﬁed is Ochrobactrum anthropi [1,2]. They are
widely regarded as environmental pathogens with low virulence
[3,4].
There is minimal literature on infections caused by
O. Intermedium, and none is associated with intravascular
infection. Ochromobactrum spp. infections largely relate to
immunocompromised patients with bacteraemias, endoph-
thalmitis and a pyogenic liver abscess [5–8]. Notably, this is the
ﬁrst documented case of infective endocarditis related to
O. intermedium in humans. Successful therapy has been achieved
with combination antibiotic therapy based on known suscepti-
bilities, including imipenem with ciproﬂoxacin/tobramycin
(Table 1).
There are few data to inform treatment or interpret mini-
mum inhibitory concentration (MIC) breakpoints. Reported
resistance to penicillins and cephalosporins is widespread, with
susceptibility to aminoglycosides, ﬂuoroquinolones, imipenem,
meropenem, tetracycline and cotrimoxazole. MICs to carba-
penems may rise after carbapenem exposure. O. anthropi is
generally susceptible to colistin, whereas O. intermedium is
resistant. Resistance mechanisms are unclear and are possibly
due to class C β-lactamases.
To our knowledge, this is the ﬁrst case of infective endo-
carditis in an immunocompromised patient related to the
emerging opportunistic pathogen O. intermedium. We advise
colleagues to remain vigilant to the virulence potential of this
organism, especially if it is recurrent and occurs in immuno-
compromised patients.© 2016 The Authors. Published by Elsevier Ltd on behal
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